PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports von Uijen, M. J. M., Derks, Y. H. W., Merkx, R. I. J., Schilham, M. G. M., Roosen, J., Privé, B. M., van Lith, S. A. M., van Herpen, C. M. L., Gotthardt, M., Heskamp, S., van Gemert, W. A. M., Nagarajah, J.

Volltext

Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma von Nutting, C.M., van Herpen, C.M.L., Miah, A.B., Bhide, S.A., Machiels, J.-P., Buter, J., Kelly, C., de Raucourt, D., Harrington, K.J.

Volltext

Prospective practice survey of management of cetuximab-related skin reactions von Lugtenberg, R. T., Boers-Doets, C. B., Witteveen, P. O., van Herpen, C. M. L., Wymenga, A. N. M., de Groot, J. W. B., Hoeben, A., del Grande, C., van Doorn, B., Koldenhof, J. J., Driessen, C. M. L., Gelderblom, H.

Volltext

[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer von van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., Menke-van der Houven van Oordt, C. W.

Volltext

Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib-Induced Hypertension von Eechoute, K, van der Veldt, A A M, Oosting, S, Kappers, M H W, Wessels, J A M, Gelderblom, H, Guchelaar, H-J, Reyners, A K L, van Herpen, C M L, Haanen, J B, Mathijssen, R H J, Boven, E

Volltext

Informal caregiver well-being during and after patients’ treatment with adjuvant chemotherapy for colon cancer: a prospective, exploratory study von Langenberg, S. M. C. H., Poort, H., Wymenga, A. N. M., de Groot, J. W., Muller, E. W., van der Graaf, W. T. A., Prins, J. B., van Herpen, C. M. L.

Volltext

Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results von Schoffelen, R, Boerman, O C, Goldenberg, D M, Sharkey, R M, van Herpen, C M L, Franssen, G M, McBride, W J, Chang, C-H, Rossi, E A, van der Graaf, W T A, Oyen, W J G

Volltext

A pharmacological rationale for improved everolimus dosing in oncology and transplant patients von Heine, R., Erp, N. P., Guchelaar, H. J., Fijter, J. W., Reinders, M. E. J., Herpen, C. M., Burger, D. M., Moes, D. J. A. R.

Volltext

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs von van der Velden, D. L., Hoes, L. R., van der Wijngaart, H., van Berge Henegouwen, J. M., van Werkhoven, E., Roepman, P., Schilsky, R. L., de Leng, W. W. J., Huitema, A. D. R., Nuijen, B., Nederlof, P. M., van Herpen, C. M. L., de Groot, D. J. A., Devriese, L. A., Hoeben, A., de Jonge, M. J. A., Chalabi, M., Smit, E. F., de Langen, A. J., Mehra, N., Labots, M., Kapiteijn, E., Sleijfer, S., Cuppen, E., Verheul, H. M. W., Gelderblom, H., Voest, E. E.

Volltext

Case Report: Imaging immune checkpoint inhibitor-induced yin-yang effects in the brain von Bol, K F, Peeters, E, van Herpen, C M L, Westdorp, H, Aarntzen, E H J G

Volltext

Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer von Willemsen, A. E. C. A. B., Knapen, L. M., de Beer, Y. M., Brüggemann, R. J. M., Croes, S., van Herpen, C. M. L., van Erp, N. P.

Volltext

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer von van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S., der Houven van Oordt, C. W. Menke-van

Volltext

Molecular Tumor Boards: current practice and future needs von van der Velden, D.L., van Herpen, C.M.L., van Laarhoven, H.W.M., Smit, E.F., Groen, H.J.M., Willems, S.M., Nederlof, P.M., Langenberg, M.H.G., Cuppen, E., Sleijfer, S., Steeghs, N., Voest, E.E.

Volltext

Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982) von van Herpen, C.M.L, Locati, L.D, Buter, J, Thomas, J, Bogaerts, J, Lacombe, D, de Mulder, P, Awada, A, Licitra, L, Bernier, J, Vermorken, J.B

Volltext

Adjuvant androgen deprivation therapy for poor-risk, androgen receptor–positive salivary duct carcinoma von van Boxtel, W., Locati, L.D., van Engen-van Grunsven, A.C.H., Bergamini, C., Jonker, M.A., Fiets, E., Cavalieri, S., Tooten, S., Bos, E., Quattrone, P., Verhaegh, G.W., Schalken, J.A., Licitra, L., van Herpen, C.M.L.

Volltext

Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review von Uijen, M.J.M., Lassche, G., van Engen-van Grunsven, A.C.H., Tada, Y., Verhaegh, G.W., Schalken, J.A., Driessen, C.M.L., van Herpen, C.M.L.

Volltext

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study von Hamberg, P, Boers-Sonderen, M J, van der Graaf, W T A, de Bruijn, P, Suttle, A B, Eskens, F A L M, Verweij, J, van Herpen, C M L, Sleijfer, S

Volltext

Better survival in patients with metastasised kidney cancer after nephrectomy: A population-based study in the Netherlands von Aben, K.K.H, Heskamp, S, Janssen-Heijnen, M.L, Koldewijn, E.L, van Herpen, C.M, Kiemeney, L.A, Oosterwijk, E, van Spronsen, D.J

Volltext

Whole-body hyperthermia in combination with systemic therapy in advanced solid malignancies von Lassche, G., Crezee, J., Van Herpen, C.M.L.

Volltext

A new, simple and objective prognostic score for phase I cancer patients von Füssenich, L.M, Desar, I.M.E, Peters, M.E.W.J, Teerenstra, S, van der Graaf, W.T.A, Timmer-Bonte, J.N.H, van Herpen, C.M.L

Volltext